The effects of irradiation on major histocompatibility complex (MHC) expression and lymphocytic infiltration in the normal rat brain and the 9L gliosarcoma brain tumor model were examined. Doses of irradiation administered were biologically equivalent to that used in the treatment of patients with malignant gliomas. No significant change in immune parameters was observed following irradiation in the normal rat brain. In the 9L gliosarcoma model irradiation did not suppress MHC expression or lymphocytic infiltration. These findings suggest that prior exposure to therapeutic irradiation need not adversely affect subsequent immunotherapies, and provide a foundation for future studies of immunomodulation in the irradiated brain.
Introduction
The limitation of current therapy for patients with malignant glioma has led to renewed interest in immunotherapy as an adjunctive mode of treatment. Immunotherapy is likely to be most effective in the early weeks following maximal cytore-duction with surgery and radiation therapy. The immunosuppressive effects of ionizing radiation are well known (Markoe and Saluk, 1987) . Irradiation has been shown to decrease major histocompatibility complex (MHC) expression and lymphocytic infiltration in melanoma (Jager et al., 1988) and reduce the effectiveness of some forms of immunotherapy (Ettinghausen et al., 1985) . However, under certain circumstances, irradiation can enhance the host immune response, and increase the efficacy of immunotherapeutic regimens (Hellstrom et al., 1978; Tilkin et al., 1981; North, 1984) . Recent work has defined a growing number of pathological and experimental situations in which the brain's immune environment is altered (Lampson, 1987) . Yet few studies have addressed the possible effects of irradiation on immune parameters in the normal or tumor-bearing brain. In this study, we examined the effects of irradiation, biologically equivalent to that used in the treatment of patients with malignant gliomas, during the time period when immunotherapy is most likely to be attempted. MHC expression and lymphocyte infiltration were examined in irradiated tumor-free brains and in the 9L gliosarcoma brain tumor model.
Materials and methods
Rats. Female CDF rats (125-150 g) were purchased from Charles River Lab. (Wilmington, MA, U.S.A.).
Antibodies. Immunocytochemistry was carried out with rabbit serum against glial fibrillary acidic protein (GFAP) (Dako) and the monoclonal antibodies OX6 (class II), OX18 (class I MHC), OX1 (LCA), W3/13 (T cells), W3/25 (T helper), OX8 (T cytotoxic/suppressor), OX33 (B cells) and OX42 (microglia) using a modification of the ABC Vectastain procedure (Whelan et al., 1986) . Briefly, sections were fixed in absolute methanol (-20 °C for 2 min) and incubated in succession with 2% normal goat serum (30 rain), diluted primary antibody (4°C, overnight), biotinylated horse antimouse IgG (pre-incubated for 30 rain with 2% normal rat serum to reduce background staining) (30 min) and ABC complex (1 h). The primary antibodies were diluted 1/10 except for OX18 which was diluted 1/3. Specific binding was visualized with a solution containing 0.05% diaminobenzidine tetrahydrochloride, 0.001% hydrogen peroxide, and 0.01 M imidazole for 10 min. P3/X63 culture supernatant was used as a negative control. For GFAP staining, the sections were serially incubated with 2% normal goat serum, rabbit anti-cow GFAP antibody (1:10,000) and biotinylated goat anti-rabbit IgG. The remainder of the procedure was unchanged from the one outlined above. Normal rabbit serum was used as a negative control.
Irradiation of tumor-free brain. The posterior half of the brains of 12 anesthetized rats was irradiated with a single dose of 1200 cGy using a GE Maximar XRay generator. This dose was biologically equivalent to the high doses of fractionated radiation used clinically in the treatment of patients with malignant gliomas (Ellis, 1971; Kramer et al., 1977; Henderson et al., 1981) . Lead foil blocks shielded the anterior half of the brain, which acted as an internal control. Two unirradiated rats served as additional controls. The animals were sacrificed on days 0 (immediately after irradiation), 1, 2 and 5 and weeks 1, 2, 3, 4, 5, 7, 10 and 16. 6 /~m coronal frozen sections of the brains were obtained through the irradiated parietal lobes and the shielded frontal lobes and examined for histologic changes (hematoxylin and eosin; H& E) and demyelination (Luxol Fast Blue), and immunocytochemically. Sections from the corresponding areas of the brains of the unirradiated rats served as additional controls. Normal lymph nodes and brains from two rats that had 20,000 units of recombinant T-interferon (IFN-T) (Biogen Biologicals) injected into the parietal lobes 3 days prior to being sacrificed served as positive controls.
Irradiation of tumor-bearing animals. The 9L gliosarcoma cell line was originally derived from tumors induced in CDF rats by weekly intravenous injections of N-nitrosomethylurea (Schmidek et al., 1971) . 2 x 10 4 9L cells were stereotactically implanted into the right caudate nucleus of CDF rats using a modification of the method of Kobayashi (Kobayashi et al., 1980) . On day 12 after implantation half the animals were anesthetized and the whole brain irradiated with a single dose of 1200 cGy. 1-2 irradiated and 1-2 non-irradiated rats were then sacrificed on days 0, 1, 2, 3, 5, 7, 10, 14 and 21. Although an attempt was made to match irradiated with non-irradiated controls as closely as possible, none of the nonirradiated tumor-bearing animals survived beyond day 14 (26 days after implantation). Coronal frozen sections were obtained through the center of the tumors and assayed immunocytochemically. With each antibody, the percentages of positively staining cells/total number of all cells from six random high-powered fields within the tumor (minimum of 900 cells) were obtained and the average determined (Whelan et al., 1985) . 
Results
In the normal rat brain, irradiation did not produce significant histologic changes, demyelination or gliosis within the time period studied. The monoclonal antibodies to class I and I! MHC antigens produced dense staining of the lymph node controls, and of dendritic cells in control brains that had been treated with IFN-7. No differences were detected in the staining patterns in irradiated brain areas compared to unirradiated areas or normal brains: class I was restricted to blood vessel walls, and class II to occasional cells associated with the leptomeninges, choroid plexus and blood vessels, and rare dendritic cells. The antibody to LCA (OX1) produced strong staining in lymphoid controls, but stained only occasional inflammatory cells in the leptomeninges in both irradiated and unirradiated areas and control brains (Fig. 1) .
In unirradiated tumor-bearing animals, no strong class I activity was seen in the tumor cells or the surrounding neural cells. In contrast, many class II + cells were seen, especially at the periphery of the tumors. The number of class II + cells increased with time after tumor implantation, reaching 40% of the ceils within selected areas of the tumor mass. Most of the class II + cells had a dendritic morphology suggestive of microglia. Rare cells (5%) had the morphologic characteristics of macrophages, lymphocytes, and occasionally astrocytes. Neither the numbers nor the proportions of cells were significantly changed following irradiation. These identifications were confirmed by serial sections stained with OX6 and antibody to GFAP and with OX6 and OX42. Two kinds of evidence suggest that the class II-positive cells were not tumor cells. In vitro, no class II was detected on 9L cells, even after incubation with IFN-T, suggesting that the 9L cells may not have the potential to express class II MHC molecules. In work to be reported separately, 9L cells were transfected with the Escherichia coli fl-galactosidase gene so that they could be identified histochemically (Lampson et al., 1989) . Double-labelling studies using the modified cells did not reveal class II-positive tumor cells within the brain. Many infiltrating leucocytes were also seen in the tumor-containing areas. As many as 40% of the cells within the tumors were LCA ÷. Analysis of lymphocyte subsets showed many T cells, including helper cells (up to 25% of all cells within the tumor mass), fewer cytotoxic/suppressor cells (up to 12%) and rare B cells (less than 5%). In control studies, 9L cells themselves did not crossreact with the antibodies to lymphocyte subsets.
Irradiation produced only slight necrosis. There was no significant effect on class I MHC expression in tumor-bearing rats. No significant change 243 was noted in class II MHC expression or lymphocytic infiltration on the first 2 days after irradiation. From day 3 onwards there was a slight increase in the numbers of class II-positive cells and lymphocytes in the irradiated tumors. However, these differences did not reach statistical significance in the Wilcoxon sign rank test (Figs. 2  and 3) .
Discussion
Under normal circumstances there is little detectable MHC expression on neural cells or lymphocytic infiltration in the brain. However, both enhanced MHC expression and lymphocytic infiltration can occur in a variety of conditions, enabling neural cells to become subjected to cellmediated immune reactions (Sobel et al., 1984; Wong et al., 1985; Lampson and Hickey, 1986; Suzumura et al., 1986; Lampson, 1987; Traugott, 1987; McGeer et al., 1988; Streit et al., 1989) . In this study, we have found that a dose of irradiation biologically equivalent to that used in the treatment of malignant glioma did not produce major histologic changes, leucocytic infiltration, or induction of MHC antigens in the brain in the time covered. Surprisingly, our study also suggested that irradiation did not decrease class II MHC expression or lymphocytic infiltration in the 9L gliosarcoma brain tumor model. These findings lay a foundation for future studies of immunomodulation in the brain when, as in the case of brain tumor patients, high doses of radiotherapy have been given previously.
